B2B only. For licensed importers and distributors. Tender authorities and healthcare institutions are also served. Not for retail or patient supply.  ·  Compliance statement
Home/Insights/India
India

How to import blood products from China to India

Importing a plasma-derived product or vaccine into India runs through the Central Drugs Standard Control Organisation (CDSCO). The shape is familiar — register the foreign site and product, then licence the import — but India adds a step most markets do not: biologicals are treated as new drugs, so a separate permission comes before the import licence.

For a Chinese plasma product, import into India is two questions. First, whether China will export it — covered in the export regulations and market-entry guide. Second, whether India will register and admit it. This page is about the second question.

The regulator and the law

The Central Drugs Standard Control Organisation (CDSCO), under the Directorate General of Health Services and the Ministry of Health and Family Welfare, regulates drugs, biologicals and vaccines under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. Imported biological products are further governed by the New Drugs and Clinical Trials (NDCT) Rules, 2019.

One point matters more than the rest: under the NDCT Rules, 2019, specified biological products are always deemed to be new drugs. This means a plasma-derived product or vaccine cannot go straight to import licensing — the new drug permission must be obtained first, even when the product is long-established in its home market.

The three authorisations, in order

An Indian import of a biological product runs through three distinct stages. They are sequential and often confused:

StageFormWhat it isWho holds it
1. New drug permissionCT-20 (formulation) / CT-19 (API)CDSCO permission to import the biological as a new drugThe Indian applicant
2. Registration CertificateForm 41Registration of the foreign site and productFiled by the authorised Indian agent
3. Import LicenceForm 10The licence to actually bring the product inThe licensed Indian importer

The key constraint: a Chinese company cannot hold the Indian registration. The foreign manufacturer must appoint an authorised Indian agent holding a wholesale drug licence (Form 20B or 21B), and that agent files the application on the CDSCO SUGAM portal. What the exporter contributes is the product file; what the Indian agent contributes is the licence and the filing.

The dossier the Chinese side must supply

The core file a Chinese exporter must supply is the same one described in the general market-entry guide, plus the documents India authenticates through its embassy:

  • Certificate of Pharmaceutical Product — the WHO-format status evidence, authenticated by the Indian embassy.
  • The drug approval number, verifiable on the NMPA database.
  • The batch release certificate — that the specific lot was state-released.
  • GMP evidence for the manufacturing site, from the Chinese authority.
  • The product dossier — specifications, analytical methods, stability data, packaging details.
  • A Plant Master File and a notarised Form 9 manufacturer's undertaking, authenticated by the Indian embassy.

Where available, a WHO prequalification certificate materially shortens the review. Registration and import licences are each valid for three years, and a facility inspection may be required at the applicant's cost.

The sequence, end to end

StepWhat happensWho does it
1. Confirm exportabilityProduct is finished, registered, batch-released — not source plasmaExporter + manufacturer
2. Appoint the Indian agentAn authorised agent with a Form 20B/21B wholesale licenceImporter side
3. New drug permissionFile for CT-20 (or CT-19) on the SUGAM portalIndian applicant
4. Register site + productForm 40 application → Form 41 Registration CertificateAuthorised Indian agent
5. Import licenceForm 8 application → Form 10 Import LicenceLicensed importer
6. Ship & clearUpload registration + licence to e-Sanchit, clear through customsLicensed importer + CDSCO

At the bill-of-entry stage, both the registration certificate and the import licence must be current and uploaded to e-Sanchit before customs will grant out-of-charge. A licence that has lapsed, or a registration that covers a different formulation, will hold the consignment.

How a Chinese export agent fits in

Wanyoda's role is the export side of this sequence. We hold the written export mandates from NMPA-licensed manufacturers and coordinate the product file — approval number verification, CPP, batch release and GMP evidence — so the Indian agent receives a complete, filing-ready dossier. We do not hold the Indian registration, because by law it is filed through an authorised Indian agent.

What this means in practice: the fastest Indian entry is one where the export-side product file is already complete and the Indian agent already holds its wholesale licence and new drug pathway. Registration then becomes adaptation and filing rather than a long evidence-gathering exercise.

The Indian constraint that matters most: biologicals are new drugs, so the new drug permission comes before the import licence. Plan the CT-20 step first — it is the one most first-time importers discover late.

Frequently asked questions

What authorisation is required to import a blood product into India?

A Registration Certificate in Form 41 from CDSCO for the foreign manufacturing site and product, followed by an Import Licence in Form 10 held by a licensed Indian importer. Biological products are treated as new drugs, so permission under CT-19/CT-20 is also required before the import licence.

Can a Chinese company hold the Indian registration?

No. Foreign manufacturers apply through an authorised Indian agent holding a wholesale drug licence (Form 20B/21B). The agent files Form 40 on the SUGAM portal; the Chinese exporter supplies the product file.

How long is a CDSCO Form 41 registration valid?

A Form 41 Registration Certificate and a Form 10 Import Licence are each valid for three years from the date of issue.

What documents does the Indian application require from the Chinese side?

A Certificate of Pharmaceutical Product (CPP) from the NMPA, a GMP certificate, the product dossier with specifications and stability data, a Plant Master File, and a notarised Form 9 manufacturer's undertaking, authenticated by the Indian embassy.

Where to go next

India

Map your Indian entry.

Tell us the product and your licence position, and we will lay out the CDSCO path — the new drug permission, the Form 41 registration and the Form 10 import licence, in the right order.